Pharmacotherapy for unresectable metastatic colorectal cancer

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.
   PubMed Web of Science ®Google Scholar
• Benson AB, Venook AP, Al-Hawary MM, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021 Mar 2;19(3):329–359.
   PubMedGoogle Scholar
• Rogers JE, Ohinata A, Dasari A, et al. Atypical metastatic presentations in colorectal cancer: a case series. Clin Colorectal Cancer. 2014;13(1):e1–4.
   PubMed Web of Science ®Google Scholar
• Eng C, Rogers JE. Current synthetic pharmacotherapy for treatment-resistant colorectal cancer: when urgent action is required. Expert Opin Pharmacother. 2019;20(5):523–534.
   PubMed Web of Science ®Google Scholar
• Ciardiello D, Martini G, Famiglietti V, et al. Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer. Cancers (Basel). 2021;13(8):1941.
   PubMed Web of Science ®Google Scholar
• National cancer institute: surveillance E, and end results program. Cancer Stat Facts: Colorectal Cancer. Accessed 21 7 7. https://seer.cancer.gov/statfacts/html/colorect.html.
   Google Scholar
• Modest DP, Martens UM, Riera-Knorrenschild J, et al. FOLFOXIRI plus panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer: the randomized, open-label, phase II VOLFI study (AIO KRK0109). J Clin Oncol. 2019;37(35):3401–3411.
   PubMed Web of Science ®Google Scholar
• Borelli B, Moretto R, Lonardi S, et al. TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. ESMO Open. 2018;3(4):e000403.
   PubMed Web of Science ®Google Scholar
• Venook AP, Donna N, Innocenti F, et al. Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (alliance). J Clin Oncol. 2016. DOI:https://doi.org/10.1200/JCO.2016.34.15_suppl.3504.
   Google Scholar
• Tejpar S, Stintzing S, Ciardiello F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol. 2017;3(2):194–201.
   PubMed Web of Science ®Google Scholar
• Andre T, Shiu KK, Kim TW, et al. Final overall survival for the phase III KN177 study: pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). J Clin Oncol. 2021;(suppl 15):39. abstr 3500. DOI: https://doi.org/10.1200/JCO.2021.39.15_suppl.3500
   Google Scholar
• Andre T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207–2218.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Chu E. Recent advances in the clinical development of immune checkpoint blockade therapy for mismatch repair proficient (pMMR)/non-MSI-H metastatic colorectal cancer. Clin Colorectal Cancer. 2018;17(4):258–273.
   PubMed Web of Science ®Google Scholar
• Overman MJ, Ernstoff MS, Morse MA, et al. Where we stand with immunotherapy in colorectal cancer: deficient mismatch repair, proficient mismatch repair, and toxicity management. Am Soc Clin Oncol Educ Book. 2018;38(38):239–247.
   PubMedGoogle Scholar
• Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36(8):773–779.
   PubMed Web of Science ®Google Scholar
• Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (checkMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–1191.
   PubMed Web of Science ®Google Scholar
• Ooki A, Shinozaki E, Yamaguchi K, et al. Immunotherapy in colorectal cancer: current and future strategies. J Anus Rectum Colon. 2021;5(1):11–24.
   PubMed Web of Science ®Google Scholar
• Cohen R, Colle R, Pudlarz T, et al. Immune checkpoint inhibition in metastatic colorectal cancer harboring microsatellite instability or mismatch repair deficiency. Cancers (Basel). 2021;13(5). DOI:https://doi.org/10.3390/cancers13051149.
   Google Scholar
• Roth MT, Das S. Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy. Expert Rev Anticancer Ther. 2021;21(2):229–238.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study. Accessed 21 7 7. https://clinicaltrials.gov/ct2/show/NCT02997228.
   Google Scholar
• Clinicaltrials.gov. A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator’s Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW). Accessed 21 7 7. https://clinicaltrials.gov/ct2/show/NCT04008030.
   Google Scholar
• Administration USFD. FDA approves pembrolizumab for adults and children with TMB-H solid tumors. Accessed 21 7 7. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors.
   Google Scholar
• Meiri E, Garrett-Mayer E, Halabi S, et al. Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): results from the targeted agent and profiling utilization registry (TAPUR) study. J Clin Oncol. 2020;38(4). DOI:https://doi.org/10.1200/JCO.2020.38.4_suppl.133.
   Google Scholar
• Antoniotti C, Marmorino F, Lonardi S, et al. Tumor mutational load, microsatellite instability and actionable mutations in metastatic colorectal cancer: results from the TRIBE2 study. J clin oncol. 2020;38(15). DOI:https://doi.org/10.1200/JCO.2020.38.15_suppl.4077.
   Google Scholar
• Strickler JH, Hanks BA, Khasraw M, et al. Tumor mutational burden as a predictor of immunotherapy response: is more always better?. Clin Cancer Res. 2021;27(5):1236–1241.
   PubMed Web of Science ®Google Scholar
• Eng C, Kim TW, Bendel J, et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019;20(6):849–861.
   PubMed Web of Science ®Google Scholar
• Fukuoka S, Hara H, Takahashi N, et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J Clin Oncol. 2020;38(18):2053–2061.
   PubMed Web of Science ®Google Scholar
• Bendell JC, Bang YJ, Chee CE, et al. A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC). J clin oncol. 2018;36(4). DOI:https://doi.org/10.1200/JCO.2018.36.4_suppl.560.
   Google Scholar
• Fakih M, Raghav KPS, Chang DZ, et al. Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC). J Clin Oncol. 2021 May 20;39(15_suppl):3560.
   Web of Science ®Google Scholar
• Gomez-Roca C, Yanez E, Im AS, et al. LEAP-005: a phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—results from the colorectal cancer cohort. J Clin Oncol. 2021 Jan 20;39(3_suppl):94.
   Web of Science ®Google Scholar
• Guo YZW, Ying J. Preliminary results of a phase 1b study of fruquintinib plus sintilimab in advanced colorectal cancer. J Clin Oncol. 2021 May 20;39(15_suppl):2514.
   Web of Science ®Google Scholar
• Bever KM, Le DT. An expanding role for immunotherapy in colorectal cancer. J Natl Compr Canc Netw. 2017;15(3):401–410.
   PubMed Web of Science ®Google Scholar
• Cohen R, Cervera P, Svrcek M, et al. BRAF-mutated colorectal cancer: what is the optimal strategy for treatment?. Curr Treat Options Oncol. 2017;18(2):9.
   PubMed Web of Science ®Google Scholar
• Mauri G, Bonazzina E, Amatu A, et al. The evolutionary landscape of treatment for BRAF(V600E) mutant metastatic colorectal cancer. Cancers (Basel). 2021;13(1). DOI:https://doi.org/10.3390/cancers13010137.
   Google Scholar
• Schirripa M, Lenz HJ. Biomarker in colorectal cancer. Cancer J. 2016;22(3):156–164.
   PubMed Web of Science ®Google Scholar
• Ursem C, Atreya CE, Van Loon K, et al. Emerging treatment options for BRAF-mutant colorectal cancer. Gastrointest Cancer. 2018;8:13–23.
   PubMedGoogle Scholar
• Grothey A, Fakih M, Tabernero J, et al. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. Ann Oncol. 2021;S0923-7534(21):1–01112.
   Google Scholar
• Cremolini C, Loupakis F, Antoniotti C, et al. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the gruppo oncologico del nord ovest. Ann Oncol. 2015;26(6):1188–1194.
   PubMed Web of Science ®Google Scholar
• Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16(13):1306–1315.
   PubMed Web of Science ®Google Scholar
• Cremolini C, Antoniotti C, Rossini D, et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21(4):497–507.
   PubMed Web of Science ®Google Scholar
• Stintzing S, Heinrich K, Tougeron D, et al. Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: the phase-II FIRE-4.5 study (AIO KRK-0116). J Clin Oncol. 2021 May 20;39(15_suppl):3502.
   Web of Science ®Google Scholar
• Tabernero J, Grothey A, Van Cutsem E, et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol. 2021;39(4):273–284.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. BRAF V600E-mutant Colorectal Cancer Study of Encorafenib Taken With Cetuximab Plus or Minus Chemotherapy (BREAKWATER). Accessed 21 7 7. https://clinicaltrials.gov/ct2/show/NCT04607421.
   Google Scholar
• Jones JC, Renfro LA, Al-Shamsi HO, et al. (Non-V600) BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer. J Clin Oncol. 2017;35(23):2624–2630.
   PubMed Web of Science ®Google Scholar
• Johnson B, Loree JM, Jacome AA, et al. Atypical, non-V600 BRAF mutations as a potential mechanism of resistance to EGFR inhibition in metastatic colorectal cancer. JCO Precis Oncol. 2019;3. DOI: https://doi.org/10.1200/PO.19.00102
   Google Scholar
• Clinicaltrials.gov. S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery. Accessed 21 7 7. https://clinicaltrials.gov/ct2/show/NCT03365882.
   Google Scholar
• Siena S, Sartore-Bianchi A, Trusolino L, et al. Abstract CT005: final results of the HERACLES trial in HER2-amplified colorectal cancer. AACR Cancer Research. Accessed 21 7 7. https://cancerres.aacrjournals.org/content/77/13_Supplement/CT005.
   Google Scholar
• Hainsworth JD, Meric-Bernstam F, Swanton C, et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from myPathway, an open-label, phase iIa multiple basket study. J Clin Oncol. 2018;36(6):536–542.
   PubMed Web of Science ®Google Scholar
• Yoshino T, Bartolomeo MD, Raghav KPS, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): final results from a phase 2, multicenter, open-label study (DESTINY-CRC01). J clin oncol. 2021;39(15_suppl):3505.
   Web of Science ®Google Scholar
• De Cuyper A, Van Den Eynde M, Machiels JP, et al. HER2 as a predictive biomarker and treatment target in colorectal cancer. Clin Colorectal Cancer. 2020;19(2):65–72.
   PubMed Web of Science ®Google Scholar
• Stickler JHZT, Ou F. 4795 - Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): initial results from the MOUNTAINEER trial. Ann Oncol. 2019;30(suppl_5):v198–v252.
   Google Scholar
• Wang HOQ, Wu X. NTRK fusion positive colorectal cancer as a unique subset of CRC with high tumor mutation burden and microsatellite instability. J Clin Oncol. 2021;39(suppl 15). abstr 3544. DOI: https://doi.org/10.200/JCO.2021.39.15_suppl3544.
   Web of Science ®Google Scholar
• Santos C, Sanz-Pamplona R, Salazar R, et al. RET-fusions: a novel paradigm in colorectal cancer. Ann Oncol. 2018;29(6):1340–1343.
   PubMed Web of Science ®Google Scholar
• Patelli G, Tosi F, Amatu A, et al. Strategies to tackle RAS-mutated metastatic colorectal cancer. ESMO Open. 2021;6(3):100156.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. HER 2 colorectal cancer. Accessed 21 7 7. https://clinicaltrials.gov/ct2/results?cond=&term=+HER+2+colorectal+cancer&cntry=&state=&city=&dist=.
   Google Scholar
• Clinicaltrials.gov. BRAF colorectal cancer. Access 21 7 7. https://clinicaltrials.gov/ct2/results?cond=&term=BRAF+colorectal+cancer&cntry=&state=&city=&dist=.
   Google Scholar
• Clinicaltrials.gov. MSI-H dmmR colorectal cancer. Accessed 21 7 7. https://clinicaltrials.gov/ct2/results?cond=&term=MSI-H+dmmR+colorectal+cancer&cntry=&state=&city=&dist=.
   Google Scholar
• Henry JT, Coker O, Chowdhury S, et al. Comprehensive clinical and molecular characterization of KRASG12C-mutant colorectal cancer. JCO Precis Oncol. 2021; (5):613–621. DOI:https://doi.org/10.1200/PO.20.00256.
   Google Scholar
• Hong DS, Fakih MG, Strickler JH, et al. KRAS(G12C) inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383(13):1207–1217.
   PubMed Web of Science ®Google Scholar
• Johnson ML, Ou SHI, Barve M, et al. KRYSTAL-1: activity and safety of adagrasib (MRTX849) in patients with colorectal cancer (CRC) and other solid tumors harboring a KRAS G12C mutation. Eur J Cancer. 2020;138:S2–S.
   Web of Science ®Google Scholar
• Clinicaltrials.gov. Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10). Accessed 21 7 7. https://clinicaltrials.gov/ct2/show/NCT04793958.
   Google Scholar
• Parseghian CM, Napolitano S, Loree JM, et al. Mechanisms of innate and acquired resistance to anti-EGFR therapy: a review of current knowledge with a focus on rechallenge therapies. Clin Cancer Res. 2019;25(23):6899–6908.
   PubMed Web of Science ®Google Scholar
• Parseghian CM, Loree JM, Morris VK, et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol. 2019;30(2):243–249.
   PubMed Web of Science ®Google Scholar
• Cremolini C, Rossini D, Dell’Aquila E, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan. JAMA Oncol. 2019;5(3):343–350.
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Pietrantonio F, Lonardi S, et al. Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: the CHRONOS trial. J Clin oncol. 2021;39(15 suppl):3506.
   PubMed Web of Science ®Google Scholar